Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8L4Z0)

• Drug Name: Napsagatran Drug Info
• Synonyms: Ro-46-6240

Indication

Disease Entry	ICD 11	Status	REF
Myocardial infarction	BA41-BA43	Discontinued in Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 6918278
  CAS Number: CAS 154397-77-0
  TTD Drug ID: DM8L4Z0

Molecule-Related Drug Atlas

Drug(s) Targeting Coagulation factor IIa (F2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Argatroban	DMFI46A	Thrombosis	DB61-GB90	Approved	[3]
Pyridoxal Phosphate	DMO2K0J	Malnutrition	5B50-5B71	Approved	[4]
Bivalirudin	DMECRX1	Thrombocytopenia	3B64	Approved	[5]
Ximelegatran	DMU8ANS	Myocardial infarction	BA41-BA43	Approved	[6]
Dabigatran	DMDI6R4	Stroke	8B20	Approved	[7]
Desirudin Recombinant	DM2BTFN	Coagulation defect	3B10.0	Approved	[8]
Human prothrombin complex concentrate	DMPHVQ1	Bleeding disorder	GA20-GA21	Approved	[9]
Lepirudin	DM1I3D5	Thrombocytopenia	3B64	Approved	[10]
Anisindione	DM2C48U	Coagulation defect	3B10.0	Approved	[11]
ATryn antithrombin	DM79Y2T	Multiple sclerosis	8A40	Approved	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor IIa (F2)	TT6L509	THRB_HUMAN	Inhibitor	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004026)
• [2] Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model. J Pharmacol Exp Ther. 1996 Apr;277(1):71-8.
• [3] Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44.
• [4] New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32.
• [5] New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8.
• [6] Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
• [7] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
• [10] Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50.
• [11] Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6.
• [12] Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779.